Loading clinical trials...
Loading clinical trials...
Phase Ib/II Study of NT219 in Combination With Pembrolizumab or Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Interventions
NT219
Locations
2
United States
Universtiy of Colorado Hospital
Aurora, Colorado, United States
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado, United States
Start Date
June 12, 2025
Primary Completion Date
February 1, 2030
Completion Date
February 1, 2031
Last Updated
December 22, 2025
NCT05039801
NCT06980038
NCT06806852
NCT04585750
NCT06636188
NCT07457346
Lead Sponsor
University of Colorado, Denver
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions